CROI 2017 Abstract e-Book

Abstract eBook

Keyword Index

KEYWORD INDEX

1077HS 772 18 F-FDG-PT/CT 238 2 drug regimen 44LB 90-90-90 114LB A3G 173 Abacavir 609 ACA 1012 Acceptability 421LB Access to care 552, 615, 926, 927 Activation 803 Acute Hepatitis C 137LB, 520

Antibodies 1055LB, 141, 177, 244, 253, 329, 67 Antibody engineering 328, 329 Antibody response 66, 279, 877 Antibody therapy 254, 437 Antibody-dependent cell-mediated cytotoxicity 328, 329 Anticoagulant therapy 409, 620 Antigen-specific responses 278 Antigen/antibody assays 278, 510 Antimicrobial resistance 80LB Antiretroviral 38, 277, 378, 409, 452LB, 455, 761, 773 Antiretroviral failure 461, 463 Antiretroviral therapy 26, 27, 214, 221, 224, 275, 293, 316, 325, 340, 343, 34LB, 367, 380, 391, 431, 438, 444, 454, 459, 461, 464, 469, 472, 474, 475, 485, 486, 491, 502, 601, 608, 613, 633, 639, 650, 652, 664, 684, 698, 700, 710, 718, 730, 745, 751, 765, 772, 776, 78, 782, 787, 799, 814, 818, 830, 837, 875, 906, 915, 916, 928, 931, 947, 952, 960, 988, 990, 994, 996, 1021, 1042, 1051, 124, 270, 271, 284, 473, 271, 291, 798, 1041, 28, 795, 823 · Adherence 671, 770, 924 · Complications 695 · Coverage 1010 · Initiation 117, 238, 344, 446, 448, 471, 476, 598, 599, 717, 920, 942, 992, 1005, 1007, 1021, 1031, 1050 · Intensification 441 · Naive 43 · Outcomes 113, 461, 463, 648, 768, 952, 1006 · Retention 836, 837, 1005, · Scale-up 994, 1046 · Activity 271 Antiviral immune response 259

Body mass index 693, 695, 699 Bone 443, 681, 819

· Renal safety 424, 649 · Biomarkers 649, 682 · Disease 680, 681, 819 · Loss 681, 682, 684 · Metabolism dysfunction 820 · Mineral density 453, 677, 678, 680, 681, 685LB, 981 · Turnover markers 820 Botswana 184, 789, 790, 988 Brain 74, 365, 374, 395, 398, 826 Brain structure 352LB, 385, 397 Breast milk 765 Broadly neutralizing antibodies 118, 242, 243, 245, 329, 330LB, 66, 67 Bronchiolitis 655 Cabotegravir 84, 439, 442, 496, 498, 499 Cancer 304, 474, 598, 661, 693 · Risk 131, 539, 599 · Screening 592 · Survival 606 Cannabinoid receptor 531 Capsid 16, 38, 155 Cardiometabolic health 622, 698, 821 Cardiovascular 628, 631 Cardiovascular disease 127, 128LB, 129, 470, 474, 611, 615, 622, 627, 629, 632, 634, 674, 693 · Risk factors 127, 575, 610, 614, 616, 618, 622, 624, 633, 635LB, 637, 640, 694, 822 Care 32 · Retention 907, 911 · Care-delivery model 1046 Caribbean 504LB Carotid intima-media thickness 617, 629, 632, 640, 822 cART 23, 215, 234, 680, 779 Cascade 115, 116, 543, 545, 546, 553, 729, 764, 832, 900, 908, 909, 910, 911, 914, 991, 1011, 1016, 1018, 1044, 1046 Cause of death 529 Cause-specific mortality 631 CBF 173 CCL20 204, 223 CCR5 169, 209, 335, 437, 945 CCR5 expression 236, 943 CD4 cell 14LB, 23, 30, 61, 62LB, 169, 450LB, 225, 226, 286, 292, 315, 467, 614, 620, 631, 740, 800, 881, 945, 993, 1006 CD40 ligand 333 CD8 cell 65, 266, 267, 268, 270, 271 Cell-associated RNA 286, 330LB, 61 Cell-to-cell transmission 180 Cellular factors/Cytokines 18, 241 Cenicriviroc 381 Central memory T cells 290 Central nervous system (CNS) 68, 69, 71, 73, 339, 342, 344, 349, 363, 369, 370, 380, 403, 426, 743, 750, 830, 829 · Disease 368, 391 · Phenotypes 374, 384 Cerebral blood flow 825 Cerebral small vessel disease 75 Cerebrospinal fluid 340, 357, 363, 364, 371, 377, 379, 386, 387 Cerebrospinal fluid viral escape 73, 349, 371, 379 Cerebrovascular 75, 399 · Disease 347 · Cell response 264, 717 · Cell ratio 72, 633, 644

Acute HIV 27, 71, 124, 189, 197, 203, 205, 249, 282, 324, 339, 344, 380, 391, 394, 446, 477, 876, 877, 886, 887, 889, 890, 901, 1022 Acute myocardial infarction 626 Acute rejection 541 Acute HIV 202 Adaptive viral load monitoring 1052 ADAR gene 259, 530 Addiction 868LB Adherence 353, 405, 419, 468, 469, 671, 675, 706, 770, 835, 925, 976, 977, 978 Adipokine 691, 696 Adipose tissue 230, 251, 627, 691, 700 Administrative data 980 Adolescents 1033, 425, 685LB, 722, 802, 807, 812, 820, 833, 834, 835, 836, 837, 838, 841LB, 859 Adults 737, 821 Advanced HIV-disease 225 Advanced liver disease 575 Adverse drug reactions 409a, 459 Adverse effects 128LB, 444, 651, 653, 664, 779, Africa 1005, 1047, 467, 607, 641, 770, 773, 781, 786, 788, 814, 836, 841LB, 920, 937 African 481 African American 417, 921 African Green Monkey 172 Age 377 Aging 133, 234, 257, 258, 352LB, 356, 361, 396, 431, 432, 643,

Keyword Index

APOBEC3 227 APOBEC3F 17 APOBEC3G/F 334 APOBEC3H polymorphisms 172 Apoptosis 312 Arterial inflammation 635LB Asia 698 Assay 300, 317 Assembly 158 Astrocyte 375 Atazanavir 127, 425 Atazanavir/ritonavir 128LB, 650 Atherosclerosis 126, 636LB

662, 663, 666, 667, 670, 672, 75 AIDS 474, 530, 633, 668, 743 AIDS events 467, 473 AIDS-defining cancers 598, 600, 602 AIDS-related lymphoma 604 Alberta 866 Alcohol 673, 709, 874

Autologous cytotoxic T-lymphocytes 122 Autologous stem cell transplantation 323 Avidity 881 Aviremic 362 B cell 785 B cell responses 249, 265LB, 313, 798 Bacterial vaginosis 210, 85, 86LB Barriers 90 Behavioral 694, 965 Bevirimat 507 Bictegravir 41, 497, 498 Biomarker 225, 278, 282, 341, 342, 386, 593, 608, 623, 630, 647, 696, 701, 827, 828, 897

ALLINI 171LB alloBMT 318

Allograft rejection 688 Allosteric inhibitor 157 Alpha 4 beta 7 64LB Alpha-1 antitrypsin 660 ALT 576 Amyloid 386 Anal cancer 592, 594, 595, 596, 597 Anal HPV 597 Anal swabs 591 Analytic treatment interruption 125, 249, 270, 336 Anemia 721 Animal model 609

Birth cohort 545 Birth rates 939 Black 912 Black MSM 872, 969, 1043 Blood flow 401 Blood-brain barrier 366, 830 BnAb 250 Body composition 695

Antenatal 776 Anti-HCV 141 Anti-HIV 391 Antibiotics 216, 91LB

CROI 2017 485